Login to Your Account



Prosensa Shares Plunge on Drisapersen Phase III Miss

By Cormac Sheridan
Staff Writer

Wednesday, September 25, 2013
Shares in Prosensa Holding NV plunged 70.3 percent last Friday on news that its exon-skipping antisense drug drisapersen failed to meet the primary endpoint of a Phase III trial in Duchenne muscular dystrophy (DMD).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription